Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NYSE:GSK NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$90.07-1.6%$91.60$79.52▼$124.00$23.14B1.32756,152 shs671,487 shsGSKGSK$52.30-0.9%$51.44$35.45▼$61.69$106.76B0.353.23 million shs2.05 million shsJNJJohnson & Johnson$257.82+0.3%$237.62$154.80▼$269.43$618.61B0.248.26 million shs5.24 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-1.55%-4.11%-0.52%-8.47%-20.21%GSKGSK-0.90%-1.55%-1.40%-11.64%+36.58%JNJJohnson & Johnson+0.25%-0.57%+7.17%+7.36%+64.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$90.07-1.6%$91.60$79.52▼$124.00$23.14B1.32756,152 shs671,487 shsGSKGSK$52.30-0.9%$51.44$35.45▼$61.69$106.76B0.353.23 million shs2.05 million shsJNJJohnson & Johnson$257.82+0.3%$237.62$154.80▼$269.43$618.61B0.248.26 million shs5.24 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-1.55%-4.11%-0.52%-8.47%-20.21%GSKGSK-0.90%-1.55%-1.40%-11.64%+36.58%JNJJohnson & Johnson+0.25%-0.57%+7.17%+7.36%+64.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.1343.36% UpsideGSKGSK 2.10Hold$53.001.34% UpsideJNJJohnson & Johnson 2.74Moderate Buy$261.261.33% UpsideCurrent Analyst Ratings BreakdownLatest JNJ, BNTX, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026JNJJohnson & Johnson TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$250.00 ➝ $300.007/13/2026JNJJohnson & Johnson Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$265.00 ➝ $287.007/10/2026JNJJohnson & Johnson Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$254.00 ➝ $263.007/9/2026GSKGSK Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/8/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$283.00 ➝ $284.007/8/2026BNTXBioNTech Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$126.00 ➝ $119.007/8/2026JNJJohnson & Johnson CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$285.00 ➝ $298.007/6/2026BNTXBioNTech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026JNJJohnson & Johnson HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$290.007/6/2026GSKGSK HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Hold6/26/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$270.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$3.25B7.02$1.31 per share68.53$96.59 per share0.93GSKGSK$43.07B2.46$5.95 per share8.79$10.32 per share5.07JNJJohnson & Johnson$94.19B6.59$14.17 per share18.20$33.85 per share7.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)GSKGSK$7.54B$3.8513.5910.403.3917.82%44.28%11.49%7/28/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6529.8120.412.5121.83%32.60%13.29%7/15/2026 (Estimated)Latest JNJ, BNTX, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026BNTXBioNTech-$2.4079N/AN/AN/A$183.75 millionN/A7/28/2026Q2 2026GSKGSK$1.27N/AN/AN/A$11.02 billionN/A7/15/2026Q2 2026JNJJohnson & Johnson$2.85N/AN/AN/A$25.02 billionN/A5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AGSKGSK$1.793.42%-7.86%46.49%N/AJNJJohnson & Johnson$5.362.08%+5.25%61.97%64 YearsLatest JNJ, BNTX, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20264/14/2026JNJJohnson & Johnsonquarterly$1.342.33%5/26/20265/26/20266/9/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74GSKGSK0.800.790.52JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%GSKGSK15.74%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%GSKGSK10.00%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableGSKGSK66,8412.02 billion1.82 billionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableJNJ, BNTX, and GSK HeadlinesRecent News About These CompaniesWelch & Forbes LLC Has $160.73 Million Position in Johnson & Johnson $JNJ1 hour ago | marketbeat.comMidwest Trust Co Lowers Position in Johnson & Johnson $JNJ1 hour ago | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by WealthShield Partners LLC1 hour ago | marketbeat.comFerguson Wellman Capital Management Inc. Has $114.65 Million Position in Johnson & Johnson $JNJ2 hours ago | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Cullinan Associates Inc.2 hours ago | marketbeat.comCitizens Financial Group Inc. RI Purchases 7,966 Shares of Johnson & Johnson $JNJ2 hours ago | marketbeat.comFifth Third Bancorp Purchases 804,298 Shares of Johnson & Johnson $JNJ2 hours ago | marketbeat.comJohnson & Johnson $JNJ Shares Acquired by Candriam S.C.A.2 hours ago | marketbeat.comBeacon Harbor Wealth Advisors Inc. Trims Holdings in Johnson & Johnson $JNJ3 hours ago | marketbeat.comJohnson & Johnson $JNJ Shares Sold by American Trust3 hours ago | marketbeat.comIs Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?July 13 at 10:35 PM | finance.yahoo.comIs Johnson & Johnson Stock Poised for New Highs as Q2 Results Approach?July 13 at 6:51 PM | zacks.comUpdate: Nasdaq Snaps 3-Day Winning Streak as Oil Jumps Amid US-Iran TensionsJuly 13 at 5:35 PM | finance.yahoo.comJNJ Vs. KO: Which Dividend Stock Is The Better Buy?July 13 at 12:22 PM | 247wallst.comIs JNJ Stock a Buy, Sell or Hold Ahead of Q2 Earnings Release?July 13 at 11:45 AM | zacks.comRoyal Bank Of Canada Raises Johnson & Johnson (NYSE:JNJ) Price Target to $287.00July 13 at 10:41 AM | marketbeat.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJuly 13 at 9:56 AM | zacks.comThe Real Case for Buying Johnson & Johnson (JNJ) Before July 15July 13 at 8:30 AM | 247wallst.comThe Real Case for Buying Johnson & Johnson (JNJ) Before July 15July 13 at 8:30 AM | 247wallst.comIs Dividend King Johnson & Johnson (JNJ) a Buy Ahead of Earnings?July 13 at 7:50 AM | tipranks.comThe Dividend Growth Roadmap That Turns $60,000 a Year Into More Than $125,000July 13 at 6:00 AM | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNJ, BNTX, and GSK Company DescriptionsBioNTech NASDAQ:BNTX$90.07 -1.42 (-1.55%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$89.21 -0.86 (-0.95%) As of 06:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.GSK NYSE:GSK$52.30 -0.48 (-0.91%) Closing price 07/13/2026 03:59 PM EasternExtended Trading$51.83 -0.47 (-0.90%) As of 06:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Johnson & Johnson NYSE:JNJ$257.82 +0.84 (+0.33%) Closing price 07/13/2026 03:59 PM EasternExtended Trading$258.11 +0.29 (+0.11%) As of 06:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
